Not for human consumption — research use only. This article is written for laboratory researchers and describes in-vitro research applications only.

Introduction

Ipamorelin is a synthetic pentapeptide studied in laboratory research as a selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), commonly referred to as the ghrelin receptor. It was first described in the peer-reviewed literature in 1998, when Raun and colleagues reported ipamorelin as a selective growth hormone secretagogue in laboratory models (European Journal of Endocrinology, 139:552–561). Since then, it has been used in receptor-pharmacology and analytical-chemistry research as a defined, small-peptide tool compound for probing GHS-R1a binding and signaling in controlled in-vitro systems.

This article reviews the molecular characteristics of ipamorelin — its sequence, non-proteinogenic residues, and physicochemical properties — and summarizes how research laboratories characterize, store, and document ipamorelin reference material for in-vitro study applications.

Molecular Structure and Sequence

Ipamorelin is a linear pentapeptide amide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Its molecular formula is C₃₈H₄₉N₉O₅, corresponding to an average molecular weight of approximately 711.85 Da (PubChem CID 9831659). Three features of the sequence are of particular interest to peptide chemists:

Non-proteinogenic residues. The N-terminal residue, Aib (α-aminoisobutyric acid), is a sterically constrained, achiral amino acid that restricts backbone flexibility and promotes turn and helical conformations. Positions 3 and 4 incorporate D-configured residues — D-2-naphthylalanine (D-2-Nal) and D-phenylalanine (D-Phe) — whose bulky aromatic side chains contribute to the hydrophobic pharmacophore explored in GHS structure–activity studies. D-amino acids also confer resistance to many common proteases in cell-free and cell-culture matrices, a property exploited in assay design.

C-terminal amidation. The C-terminus is present as a primary amide (Lys-NH₂) rather than a free carboxylate. Amidation removes a negative charge, increases the net positive character of the molecule at neutral pH (the lysine side chain and the N-terminus are protonated), and is a recurring modification in synthetic GHS peptides.

Compact size. At five residues, ipamorelin is among the smallest GHS peptides reported, which simplifies solid-phase synthesis, purification by reversed-phase chromatography, and unambiguous mass-spectrometric identification.

Selective GHS-R1a Agonism in Laboratory Research

The growth hormone secretagogue receptor type 1a (UniProt Q92847) is a G protein-coupled receptor whose endogenous ligand is ghrelin. In laboratory receptor-binding research, ipamorelin is employed as a selective GHS-R1a agonist reference compound. Its original 1998 characterization positioned it as the first selective compound of its class, based on laboratory assays comparing secretagogue activity against off-target hormonal readouts.

In-vitro study models commonly reported in the literature include:

• Radioligand competition binding assays using membrane preparations from GHS-R1a–expressing cell lines, which quantify displacement of labeled ligands and yield affinity estimates for structure–activity comparisons.
• Second-messenger assays in transfected cell systems (for example, calcium mobilization or inositol phosphate accumulation readouts), which confirm functional agonism downstream of receptor occupancy.
• Selectivity panels in which binding or functional activity is measured across related peptide receptors, establishing the specificity profile of the compound under identical assay conditions.

These cell-based models allow precise control of exposure concentration and time, making them the standard setting for comparative receptor pharmacology of peptide ligands.

Analytical Characterization of Reference Standards

Before a peptide lot is used in sensitive receptor assays, research laboratories verify identity and purity with orthogonal analytical methods:

• Reversed-phase HPLC (RP-HPLC) with UV detection (typically 214 nm for the peptide bond and 280 nm for aromatic residues) provides a chromatographic purity profile. Deletion sequences, diastereomers, and oxidation products appear as distinct peaks, and peak-area percent is reported on the certificate of analysis.
• Mass spectrometry (commonly ESI-MS) confirms molecular identity by matching the observed monoisotopic or average mass to the theoretical value for C₃₈H₄₉N₉O₅ (approximately 711.85 Da). High-resolution MS can additionally confirm elemental composition.
• Amino acid analysis following acid hydrolysis verifies residue composition against the theoretical Aib/His/Nal/Phe/Lys ratio, provided calibrated standards for the non-proteinogenic residues are used.
• Chiral analysis (for example, chiral HPLC or GC-MS of derivatized hydrolysates) may be applied to confirm the D-configuration at positions 3 and 4, since epimerization during synthesis would alter receptor-assay results.

Because even minor impurities can shift dose–response curves in receptor assays, COA documentation of both chromatographic purity and mass confirmation is considered essential before a lot enters cell-based testing.

Lyophilized Sample Storage and Handling

Ipamorelin reference material is typically supplied as a lyophilized powder. Standard laboratory practice for lyophilized peptides includes storage at −20 °C or below in desiccated, light-protected conditions, with containers tightly sealed to prevent moisture uptake. Laboratories commonly divide material into single-use aliquots upon receipt to minimize freeze–thaw cycling, and allow sealed vials to equilibrate to room temperature before opening to avoid condensation on the hygroscopic powder. Handling and weighing are performed with calibrated analytical balances in low-humidity environments, and all transfers are recorded in laboratory notebooks or LIMS for traceability.

Documentation and Verification of Research Formulations

Research formulations prepared from reference standards are documented with the lot number, supplier COA, storage conditions, preparation date, solvent system, and nominal concentration. Verification records typically reference the analytical methods above — HPLC purity, MS identity, and appearance — so that any vial used in an assay can be traced back to its characterization data. This documentation chain supports data integrity in regulated or GLP-adjacent laboratory environments and allows retrospective review if assay results require investigation.

Not for human consumption — research use only. Ipamorelin is supplied strictly as a laboratory reference material for in-vitro research. It is not for human or veterinary use, and no medical, therapeutic, or dosing claims are made or implied in this article.

References

• National Center for Biotechnology Information. PubChem Compound Summary for CID 9831659, Ipamorelin (C₃₈H₄₉N₉O₅). https://pubchem.ncbi.nlm.nih.gov/compound/9831659
• UniProtKB. Q92847 — Growth hormone secretagogue receptor type 1 (GHSR), Homo sapiens. https://www.uniprot.org/uniprotkb/Q92847/entry
• Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/